Continuous glucose monitor data on semaglutide — Libre 3 trends

hans_munich said:

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Worth separating that from glycaemic control, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

SarahChen_PharmD said:

Steady state is the thing most people miss.

This is exactly what I could not find anywhere else. Sending this to two other people who asked me the same thing last week.

hans_munich said:

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

One concrete data point for the thread. Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Moderator note: a couple of off-topic posts removed. Carry on.